# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Stifel analyst Laura Prendergast reinstates Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and announces $8 price target.
4 biotech stocks—ALDX, ALEC, BDTX, CHRS—show strong week-on-week momentum ranking gains and improving technical indicators.
Guggenheim analyst Brad Canino initiates coverage on Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy rating and announces...
HC Wainwright & Co. analyst Robert Burns maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and lowers the pri...
Raymond James analyst Sean McCutcheon reinstates Black Diamond Therapeutic (NASDAQ:BDTX) with a Outperform and announces $11...
Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimat...
Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics' BDTX-4933 for solid tumors for ...